IL42314A - Pharmaceutical composition containing a glycyrrehetinic acid derivative and an antacid for the treatment of gastritis - Google Patents
Pharmaceutical composition containing a glycyrrehetinic acid derivative and an antacid for the treatment of gastritisInfo
- Publication number
- IL42314A IL42314A IL42314A IL4231473A IL42314A IL 42314 A IL42314 A IL 42314A IL 42314 A IL42314 A IL 42314A IL 4231473 A IL4231473 A IL 4231473A IL 42314 A IL42314 A IL 42314A
- Authority
- IL
- Israel
- Prior art keywords
- antacid
- pharmaceutical composition
- acid
- composition according
- glycyrrhetinic acid
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 12
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 title claims abstract 8
- 229940069428 antacid Drugs 0.000 title claims abstract 6
- 239000003159 antacid agent Substances 0.000 title claims abstract 6
- 230000001458 anti-acid effect Effects 0.000 title claims abstract 6
- 208000007882 Gastritis Diseases 0.000 title claims abstract 3
- 239000002253 acid Substances 0.000 title abstract 4
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical class C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims abstract 10
- 150000003839 salts Chemical class 0.000 claims abstract 4
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims abstract 3
- 229960003720 enoxolone Drugs 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims abstract 3
- 231100000252 nontoxic Toxicity 0.000 claims abstract 3
- 230000003000 nontoxic effect Effects 0.000 claims abstract 3
- 150000001399 aluminium compounds Chemical class 0.000 claims abstract 2
- -1 antacid aluminium compound Chemical class 0.000 claims abstract 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract 2
- 230000001562 ulcerogenic effect Effects 0.000 claims abstract 2
- 238000004040 coloring Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 abstract 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 abstract 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 abstract 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 abstract 1
- 229940001007 aluminium phosphate Drugs 0.000 abstract 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract 1
- UTUUIUQHGDRVPU-UHFFFAOYSA-K aluminum;2-aminoacetate;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Al+3].NCC([O-])=O UTUUIUQHGDRVPU-UHFFFAOYSA-K 0.000 abstract 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 229910052797 bismuth Inorganic materials 0.000 abstract 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 abstract 1
- 229910000019 calcium carbonate Inorganic materials 0.000 abstract 1
- 235000010216 calcium carbonate Nutrition 0.000 abstract 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 abstract 1
- 239000001095 magnesium carbonate Substances 0.000 abstract 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 abstract 1
- 235000014380 magnesium carbonate Nutrition 0.000 abstract 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 abstract 1
- 239000000347 magnesium hydroxide Substances 0.000 abstract 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 abstract 1
- 235000012254 magnesium hydroxide Nutrition 0.000 abstract 1
- 239000000391 magnesium silicate Substances 0.000 abstract 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 abstract 1
- 235000019793 magnesium trisilicate Nutrition 0.000 abstract 1
- 229940099273 magnesium trisilicate Drugs 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 150000007530 organic bases Chemical class 0.000 abstract 1
- 230000000737 periodic effect Effects 0.000 abstract 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 abstract 1
- 235000017557 sodium bicarbonate Nutrition 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1401360 Pharmaceutical compositions BIOREX LABORATORIES LTD 29 Nov 1973 [18 Dec 1972] 58355/72 Heading A5B Pharmaceutical compositions for use in the treatment of gastritis in dosage unit form comprise 1-100 mg of at least one non-ulcerogenic, anti-inflammatory active derivative of glycyrrhetinic acid (selected from the esters, hemiesters and hemiester salts thereof e.g. the disodium salt of glycyrrhetininc acid hemisuccinate, the salts of glycyrrhetinic acid with non-toxic organic bases; the salts of glycyrrhetinic acid and its hemiesters with bismuth, zinc or a metal of Group IIA, IIIA or VIII of the Periodic Table; and the amides of glycyrrhetininc acid and of acylated glycyrrhetininc acid), in admixture with 1-70% by weight, referred to the total weight of the composition, of at least one antacid, non-toxic aluminium compound (such as aluminium hydroxide, aluminium magnesium silicate, aluminium phosphate, or dihydroxyaluminium aminoacetate). The antacid aluminium compound may be partially replaced by other known antacid compounds e.g. calcium carbonate, magnesium carbonate, magnesium hydroxide, magnesium trisilicate or sodium bicarbonate. The composition may be administered orally in the form of a tablet.
[GB1401360A]
Claims (2)
1. -70$ by weight, referred to the total weight of the composition, of at least one antacid, non-toxic aluminium compound(as hereinbefore defined). 2. A pharmaceutical composition according to claim 1 wherein said dosage unit has a weight of 0.10-3.0 g. 5. A pharmaceutical composition according to claim 2, wherein said dosage unit has a weight of 0.
2. -2.0 g. 4. pharmaceutical composition according to any of the preceding claims, an wherein the glycyrrhetinic acid derivative is present in amount of from 10-50 mg. 5. A pharmaceutical composition according to any of the preceding claims, wherein the antacid is present in an amount of from 15-60 by veight. 6. A pharmaceutical composition according to any of the preceding claims, wherein the antacid aluminium compound is partially replaced by other known antacid compounds. 7. pharmaceutical composition according to any of the preceding claims, wherein the glycyrrhetinic acid derivative ίε the dlsodium salt of glycyrrhetinic acid hemisuccinate. 8. A pharmaceutical composition according to any of the preceding claims, which additionally comprises at least one pharmaceutical diluent or carrier and/or at least one flavouring agent and/or at least one sweetening agent and/or at least one colouring material. 9. A pharmaceutical composition according to claim , substantially as hereinbefore described and exemplified*
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB5835572A GB1401360A (en) | 1972-12-18 | 1972-12-18 | Pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL42314A0 IL42314A0 (en) | 1973-07-30 |
| IL42314A true IL42314A (en) | 1976-09-30 |
Family
ID=10481403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL42314A IL42314A (en) | 1972-12-18 | 1973-05-20 | Pharmaceutical composition containing a glycyrrehetinic acid derivative and an antacid for the treatment of gastritis |
Country Status (10)
| Country | Link |
|---|---|
| AU (1) | AU476390B2 (en) |
| BE (1) | BE802701A (en) |
| CA (1) | CA1018457A (en) |
| DE (1) | DE2360889A1 (en) |
| FR (1) | FR2210400B1 (en) |
| GB (1) | GB1401360A (en) |
| IE (1) | IE38521B1 (en) |
| IL (1) | IL42314A (en) |
| NL (1) | NL7317237A (en) |
| ZA (1) | ZA732439B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES8307096A1 (en) * | 1981-06-01 | 1983-07-01 | Orion Yhtymae Oy | Tablets which do not damage the oesophagus. |
| GB2122893B (en) * | 1982-06-30 | 1985-06-26 | Biorex Laboratories Ltd | Glycyrrhetinic acid compositions |
| AU553789B2 (en) * | 1982-06-30 | 1986-07-24 | Biorex Laboratories Ltd. | Glycyrrhetinic acid derivatives in cream compositions |
| US4861591A (en) * | 1987-11-18 | 1989-08-29 | American Home Products Corporation | Formulations for hygroscopic pharmaceuticals |
-
1972
- 1972-12-18 GB GB5835572A patent/GB1401360A/en not_active Expired
-
1973
- 1973-04-09 ZA ZA732439A patent/ZA732439B/en unknown
- 1973-05-20 IL IL42314A patent/IL42314A/en unknown
- 1973-07-23 BE BE133790A patent/BE802701A/en not_active IP Right Cessation
- 1973-07-30 FR FR7327833A patent/FR2210400B1/fr not_active Expired
- 1973-11-16 IE IE2082/73A patent/IE38521B1/en unknown
- 1973-11-30 AU AU63127/73A patent/AU476390B2/en not_active Expired
- 1973-12-06 DE DE2360889A patent/DE2360889A1/en not_active Withdrawn
- 1973-12-17 NL NL7317237A patent/NL7317237A/xx not_active Application Discontinuation
- 1973-12-17 CA CA188,350A patent/CA1018457A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DE2360889A1 (en) | 1974-06-20 |
| CA1018457A (en) | 1977-10-04 |
| AU476390B2 (en) | 1976-09-16 |
| AU6312773A (en) | 1975-06-05 |
| ZA732439B (en) | 1974-03-27 |
| IL42314A0 (en) | 1973-07-30 |
| FR2210400A1 (en) | 1974-07-12 |
| IE38521L (en) | 1974-06-18 |
| NL7317237A (en) | 1974-06-20 |
| GB1401360A (en) | 1975-07-16 |
| FR2210400B1 (en) | 1977-07-15 |
| IE38521B1 (en) | 1978-03-29 |
| BE802701A (en) | 1974-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3773946A (en) | Triglyceride-lowering compositions and methods | |
| IE38520L (en) | Pharmaceutical composition. | |
| ES8107231A1 (en) | Cephem and cepham compounds, processes for their preparation, pharmaceutical compositions containing them. | |
| SE7614258L (en) | PROCEDURE FOR THE PREPARATION OF CHINAZOLO DERIVATIVE | |
| ES480605A1 (en) | o-Substituted (+)-cyanidan-3-ol derivatives, method for their preparation, as well as pharmaceutical compositions containing these compounds and their preparation. | |
| IL42314A (en) | Pharmaceutical composition containing a glycyrrehetinic acid derivative and an antacid for the treatment of gastritis | |
| EP0028336B1 (en) | Derivative of creatinol-o-phosphate having therapeutical action, process for the preparation thereof and related pharmaceutical compositions | |
| IL65787A (en) | Antiviral pharmaceutical compositions containing alpha,alpha-dialkyl-adamantylamines | |
| US3787581A (en) | Pharmaceutical compositions and methods of treatment | |
| US3501577A (en) | Method of treating hypertension with alkali metal salts of zinc diethylenetriaminepentaacetate | |
| GB906331A (en) | Appetite-reducing compositions comprising phenylamino propane derivatives | |
| EP0340540B1 (en) | Agent for the prophylaxis of a heart infarct and for the prevention of another infarct | |
| ES469804A1 (en) | 6-Azaoligocycloalkylmethyleneaminopenam compounds | |
| GB1265627A (en) | ||
| ES8305759A1 (en) | Pyrrolidinone derivatives, their preparation and pharmaceutical compositions containing them. | |
| US3766168A (en) | N6-(chlorobuten - 2 - yl)-adenosines and processes for the preparation thereof | |
| US3887706A (en) | N6-(3-Chlorobuten-2-yl)-adenosines as anti-inflammatory agents | |
| GB1276589A (en) | 0-alkyl-6-azauracil compounds and compositions containing the same | |
| US2611732A (en) | Compositions containing mixtures of 4-aminosalicylic acid and its basic calcium salt | |
| GB1350929A (en) | Pharmaceutical compositions | |
| US2598004A (en) | Stabilized tetrathiodilactic and tetathiodiglycollic acid pharmaceutical | |
| US3501576A (en) | Method of treating hypertension with alkali metal salts of zinc trans - 1,2 - diaminocyclohexane-n,n,n',n'-tetraacetate | |
| US3311607A (en) | Neomycin pamoate | |
| GB1217822A (en) | Pharmaceutical compositions | |
| US4093719A (en) | Antiarthritic compositions comprising bis[(trialkyl-phosphine)gold(I)]sulfides and methods of producing antiarthritic activity |